RSS-Feed abonnieren
DOI: 10.5935/2526-8732.20220348
Assessment of body mass index and its relationship with breast cancer survival in a clinical oncology service in the Federal District
Avaliação do índice de massa corporal e sua relação com a sobrevida ao câncer de mama em um serviço de oncologia clínica do Distrito Federal Financial support: None to declare.
ABSTRACT
Objective: The purpose of this study was to analyze the relationship between obesity and clinical outcomes in breast cancer patients by evaluating the mean body mass index (BMI) and overall survival.
Material and Methods: The research's method consisted of a retrospective observational and descriptive study without intervention, carried out in a public oncology service in Brazils Federal District. We selected breast cancer patients with hormonal expression positivity in follow-up from January 2016 to December 2020.
Results: 305 female patients were evaluated, aged between 33 and 92 years old (average age of 59). Most patients were over 55 years old (63.3%). The mean weight of the patients was 71.70±9.10 kilograms. Regarding BMI, 38.7% of patients were classified as obese. As for the immunohistochemical classification (IHC), 72.9% of the patients were luminal B. Among the patients in which the initial treatment was registered, 56.1% received hormone therapy, while 43.9% received chemotherapy. The intention to treat in most patients was curative. Most patients had disease staging between II and III. As for the outcome, most patients were still undergoing treatment (83.0%) at the time of data collection. Correlating the IHC classification with patient survival, there was no significant difference between patient's classified as luminal A and those classified as luminal B (p: 0.342). There was also no significant difference between non-obese and obese patients in the assessment of overall survival and weight (p: 0.917).
Conclusion: Despite the high prevalence of obesity in the studied population, the overall survival of this group did not differ from the non-obese group, even in the analyzes by IHC profile.
RESUMO
Objetivo: O objetivo deste estudo foi analisar a relação entre obesidade e desfechos clínicos em pacientes com câncer de mama, avaliando o índice de massa corporal (IMC) médio e a sobrevida global.
Material e Métodos: O método da pesquisa consistiu em um estudo observacional retrospectivo e descritivo sem intervenção, realizado em um serviço público de oncologia do Distrito Federal. Selecionamos pacientes com câncer de mama com positividade de expressão hormonal em acompanhamento de janeiro de 2016 a dezembro de 2020.
Resultados: Foram avaliadas 305 pacientes do sexo feminino, com idade entre 33 e 92 anos (idade média de 59). A maioria dos pacientes tinha mais de 55 anos (63,3%). O peso médio dos pacientes foi de 71,70±9,10kg. Em relação ao IMC, 38,7% dos pacientes foram classificados como obesos. Quanto à classificação imuno-histoquímica (IHQ), 72,9% dos pacientes eram luminal B. Entre os pacientes em que o tratamento inicial foi registrado, 56,1% receberam terapia hormonal, enquanto 43,9% receberam quimioterapia. A intenção de tratar na maioria dos pacientes foi curativa. A maioria dos pacientes apresentou estadiamento da doença entre II e III. Quanto ao desfecho, a maioria dos pacientes ainda estava em tratamento (83,0%) no momento da coleta de dados. Correlacionando a classificação do IHQ com a sobrevida do paciente, não houve diferença significativa entre os pacientes classificados como luminal tipo A e os classificados como luminal tipo B (p: 0,342). Também não houve diferença significativa entre pacientes não obesos e obesos na avaliação da sobrevida global e peso (p: 0,917).
Conclusão: Apesar da alta prevalência de obesidade na população estudada, a sobrevida global deste grupo não diferiu do grupo não obeso, mesmo nas análises por perfil IHC.
Publikationsverlauf
Eingereicht: 25. April 2022
Angenommen: 19. August 2022
Artikel online veröffentlicht:
06. Oktober 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Kamila Fernandes Ferreira, Luiza Nardin Weis, Leandro Almeida Assunção, Eduarda Sabá Cordeiro de Oliveira, Rafael Amaral de Castro. Assessment of body mass index and its relationship with breast cancer survival in a clinical oncology service in the Federal District. Brazilian Journal of Oncology 2022; 18: e-20220348.
DOI: 10.5935/2526-8732.20220348
-
REFERENCES
- 1 Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimate/2020 – Cancer incidence in Brazil. Rio de Janeiro: INCA; 2019
- 2 Silva PA, Riul SS. Câncer de mama: fatores de risco e detecção precoce. Rev Bras Enferm 2011; Dec; 64 (06) 1016-1021
- 3 Wanderley EN, Ferreira VA. Obesidade: uma perspectiva plural. Ciênc Saúde Colet [Internet] 2010; Jun; 15 (01) 185-194 [cited YEAR Mo Day]; Available from: https://www.scielosp.org/article/csc/2010.v15n1/185-194/pt/
- 4 Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica (ABESO). Diretrizes brasileiras de obesidade 2016 [Internet]. 4a . São Paulo: ABESO; 2016. [access in YEAR Mo Day]. Available from: https://abeso.org.br/wp-content/uploads/2019/12/Diretrizes-Download-Diretrizes-Brasileiras-de-Obesidade-2016.pdf
- 5 Araujo MLD, Andrade MLSS, Prado LVS, Silva P, Cabral PC, Arruda IKG. Precisão do IMC em diagnosticar o excesso de gordura corporal avaliada pela bioimpedância elétrica em universitários. Nutr Clín Diet Hosp [Internet] 2018; 38 (03) 154-160 [cited YEAR Mo Day]; Available from: https://pesquisa.bvsalud.org/portal/resource/pt/ibc-175592
- 6 Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol [Internet] 2017; 960: 1-17 [cited YEAR Mo Day]; Available from: https://pubmed.ncbi.nlm.nih.gov/28585193/
- 7 Papa A, Barbosa C, Pirfo L André, Murad M, Moura G. et al. Impact of obesity on prognosis of breast câncer. Rev Bras Oncol Clin [Internet] 2013; 9 (31) 25-30 [cited YEAR Mo Day]; Available from: https://www.sboc.org.br/sboc-site/revista-sboc/pdfs/31/artigo3.pdf
- 8 Pinheiro A, José N, Barreto Neto S, Rio JA, Souza NJ, Crusoé D. et al. Association between body mass index and breast cancer in patients from Salvador, Bahia. Rev Bras Mastologia [Internet] 2014; Jul/Set; 24 (03) 76-81 [cited YEAR Mo Day]; Available from: https://www.mastology.org/wp-content/uploads/2015/06/MAS_v24n3_76-81.pdf
- 9 Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status - a meta-analysis. Int J Cancer 2009; Feb; 124 (03) 698-712
- 10 Ritte R, Lukanova A, Berrino F, Dossus L, Tjønneland A, Olsen A. et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res 2012; May; 14 (03) R76-R76
- 11 Iwase T, Wang X, Shrimanker TV, Kolonin MG, Ueno NT. Body composition and breast cancer risk and treatment: mechanisms and impact. Breast Cancer Res Treat 2021; Jun; 186 (02) 273-283
- 12 Cirqueira M, Amaral M, Moreira R, Soares L, Freitas Júnior R. Molecular subtypes of breast cancer. Femina [Internet] 2011; Oct; 39 (10) 499-503 [cited YEAR Mo Day]; Available from: http://files.bvs.br/upload/S/0100-7254/2011/v39n10/a2965.pdf
- 13 Harbeck N, Thomssen C, Gnant M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel) 2013; May; 8 (02) 102-109
- 14 Carmo PG, Leite ICG, Guerra MR. Sobrevida de mulheres com câncer de mama subtipo luminal assistidas em Juiz de Fora, MG. Rev Bras Mastol 2016; Sep; 26 (03) 118-125
- 15 García Fernández A, Chabrera C, Font MG, Fraile M, Lain JM, Gónzalez S. et al. Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification. Clin Translat Oncol 2014; Oct; 17 (03) 238-246
- 16 Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P. et al. Breast cancer. Nat Rev Dis Primers [Internet] 2019; Sep; 5 (01) 66-66 [cited YEAR Mo Day]; Available from: https://pubmed.ncbi.nlm.nih.gov/31548545-breast-cancer/?from_term=Nadia+Harbeck+2019&from_filter=pubt.review&from_sort=date
- 17 Rowe P. Essential statistics for the pharmaceutical sciences. Chichester: John Wiley & Sons, Inc.; 2016
- 18 Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ. et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer. JAMA Oncol 2016; Nov; 2 (11) 1477-1486
- 19 Peres VC, Veloso DLC, Xavier RM, Salge AKM, Guimarães JV. Breast cancer in women: recurrence and survival at five years. Texto Contexto Enferm 2015; Jul/Sep; 24 (03) 740-747 [cited YEAR Mo Day]; Available from: https://www.scielo.br/j/tce/a/t5htL5Mvxx89RwpvgqhvSjd/?lang=pt&format=pdf
- 20 Leal JHS, Cubero D, Del Giglio A. Hormonioterapia paliativa em câncer de mama: aspectos práticos e revisão da literatura. Rev Bras Clin Med 2010; 8 (04) 338-343
- 21 Fortner RT, Katzke V, Kühn T, Kaaks R. Obesity and breast cancer. Recent Results Cancer Res [Internet] 2016; 208: 43-65 [cited YEAR Mo Day]; Available from: https://pubmed.ncbi.nlm.nih.gov/27909901/
- 22 Caleffi M, Simon S, Bines J, Werutsky G, Nunes JS, Pacheco FC. et al. The AMAZONA project: retrospective cohort study describing breast cancer patients' characteristics and survival in Brazil. J Glob Oncol 2018; Oct; 4 (Suppl 2): S219-S221